ACC recommends diabetes meds to reduce CV risk in those with type 2 diabetes

Based on new data, ACC recommends that health care providers consider initiating sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) with the goal of reducing cardiovascular risk in patients who have type 2 diabetes.